Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Elranatamab

Geo Regions

Important Notice Regarding the Scientific Information You Have Requested

You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven. 

Please acknowledge that you understand this before proceeding.

Elranatamab

Share to an HCP

Overview + Rationale

  • B-cell maturation antigen (BCMA) is a tumor necrosis factor receptor superfamily member that is expressed predominantly on mature B cells1
  • BCMA mediates survival of antibody-secreting plasma cells after binding to its ligands BAFF (B-cell activating factor of the TNF family) and APRIL (a proliferation inducing ligand)2
  • In multiple myeloma, BCMA is widely expressed on malignant plasma cells1

Mechanism of Action

Stage of Development

Elranatamab is being investigated as a single agent and in combination with other agent(s) in the following disease settings. 

small icon representing Hematologic Cancer

Relapsed/Refractory Multiple Myeloma

Phase 1B Combination

Phase 1B/2 Combination and Monotherapy*

Phase 2 Monotherapy*

Phase 3 Monotherapy

Phase 3 Monotherapy and Combination
small icon representing Hematologic Cancer

Newly Diagnosed Multiple Myeloma (Transplant Ineligible)

Phase 3 Combination
small icon representing hematologic cancer

Newly Diagnosed Multiple Myeloma (Post-Transplant Maintenance)

Phase 3 Monotherapy
small icon representing hematologic cancer

Multiple Myeloma Double–Class Exposed

Phase 3 Monotherapy and Combination
This information is current as of August 5th 2025.

*Closed to Enrollment

BCMA=B-cell maturation antigen; CD=cluster of differentiation; CRS=cytokine release syndrome; IFN=interferon; IL=interleukin; NT=neurotoxicity; TNF=tumor necrosis factor.

REFERENCES:  1.  National Cancer Institute.  Cancer.gov https://www.cancer.gov/publications/dictionaries/cancer-drug/def/elranatamab Accessed Aprill 13, 2025 ; 2. Coquery CM, Erickson LD. Regulatory roles of the tumor necrosis factor receptor BCMA. Crit Rev Immunol. 2012;32:287-305; 3. ELREXFIO™ (elranatamab-bcmm). Prescribing Information. New York, NY: Pfizer; 2023; 4. Abramson HN. Int J Mol Sci. 2020;21:5192. 5. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06215118; https://clinicaltrials.gov/study/NCT05675449; https://clinicaltrials.gov/study/NCT05090566; https://clinicaltrials.gov/study/NCT04649359; https://clinicaltrials.gov/study/NCT05228470; https://clinicaltrials.gov/study/NCT06152575; https://clinicaltrials.gov/study/NCT05014412; https://clinicaltrials.gov/study/NCT05317416; https://clinicaltrials.gov/study/NCT05020236; https://clinicaltrials.gov/study/NCT05623020;  Accessed July7, 2025.